{"entity":{"id":"nct04159142","kind":"trial","name":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer","aka":[],"tldr":"A phase 2 trial of nab-paclitaxel, carboplatin and capecitabine in triple-negative breast cancer, run by Hebei Medical University Fourth Hospital, now recruiting.","summary":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer is a phase 2, randomised interventional study registered as NCT04159142 by Hebei Medical University Fourth Hospital, with a registry enrolment figure of 414 participants, started 2019-11-20 and due to reach its primary completion in 2026-06-20. Interventions recorded: Nab-paclitaxel + Carboplatin; Nab-paclitaxel + Capecitabine. Conditions listed: Triple Negative Breast Cancer; Nab-paclitaxel. Triple-negative eligibility wording from the registry: \"Histologically confirmed triple negative breast cancer;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04159142","url":"https://clinicaltrials.gov/study/NCT04159142"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["nab-paclitaxel","carboplatin","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04159142","phase":"2","setting":"Clinical Study of Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer","sponsor":"Hebei Medical University Fourth Hospital","enrolled":414,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04159142/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}